Business Description
Satellos Bioscience Inc. is a Canadian biotechnology company founded in 2018 and based in Toronto, focused on developing treatments for muscle-wasting diseases, with operations also in Australia. Its lead program is SAT-3247, a pill-form drug being developed to treat Duchenne muscular dystrophy, a serious and progressive muscle condition. The company conducts its research using a proprietary laboratory system that mimics the natural environment of muscle stem cells, helping scientists identify and test potential therapies. Satellos works with the Ottawa Hospital Research Institute and the University of British Columbia to advance its drug development efforts.
